Zobrazeno 1 - 10
of 310
pro vyhledávání: '"Andrew H Sims"'
Autor:
Joy Edwards-Hicks, Huizhong Su, Maurizio Mangolini, Kubra K. Yoneten, Jimi Wills, Giovanny Rodriguez-Blanco, Christine Young, Kevin Cho, Heather Barker, Morwenna Muir, Ania Naila Guerrieri, Xue-Feng Li, Rachel White, Piotr Manasterski, Elena Mandrou, Karen Wills, Jingyu Chen, Emily Abraham, Kianoosh Sateri, Bin-Zhi Qian, Peter Bankhead, Mark Arends, Noor Gammoh, Alex von Kriegsheim, Gary J. Patti, Andrew H. Sims, Juan Carlos Acosta, Valerie Brunton, Kamil R. Kranc, Maria Christophorou, Erika L. Pearce, Ingo Ringshausen, Andrew J. Finch
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-16 (2022)
MYC activation can sensitise cells to apoptosis upon glutamine withdrawal. Here the authors show that MYC activation enhances global transcription and translation that creates a metabolic demand, while glutamine limitation causes a metabolic demand a
Externí odkaz:
https://doaj.org/article/f58e694b2f6c429fb6bed6c1ae69a6f7
Autor:
Rosamaria Lappano, Marianna Talia, Francesca Cirillo, Damiano Cosimo Rigiracciolo, Domenica Scordamaglia, Rita Guzzi, Anna Maria Miglietta, Ernestina Marianna De Francesco, Antonino Belfiore, Andrew H. Sims, Marcello Maggiolini
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 39, Iss 1, Pp 1-22 (2020)
Abstract Background Hypoxia plays a relevant role in tumor-related inflammation toward the metastatic spread and cancer aggressiveness. The pro-inflammatory cytokine interleukin-1β (IL-β) and its cognate receptor IL1R1 contribute to the initiation
Externí odkaz:
https://doaj.org/article/8a89ee80ba7942e7bce4d406d1090c33
Autor:
Arran K. Turnbull, Cigdem Selli, Carlos Martinez-Perez, Anu Fernando, Lorna Renshaw, Jane Keys, Jonine D. Figueroa, Xiaping He, Maki Tanioka, Alison F. Munro, Lee Murphy, Angie Fawkes, Richard Clark, Audrey Coutts, Charles M. Perou, Lisa A. Carey, J. Michael Dixon, Andrew H. Sims
Publikováno v:
BMC Bioinformatics, Vol 21, Iss 1, Pp 1-10 (2020)
Abstract Background High-throughput transcriptomics has matured into a very well established and widely utilised research tool over the last two decades. Clinical datasets generated on a range of different platforms continue to be deposited in public
Externí odkaz:
https://doaj.org/article/35931cd60eb849c58eee6a74c308610f
Autor:
Rachel Eyre, Denis G. Alférez, Angélica Santiago-Gómez, Kath Spence, James C. McConnell, Claire Hart, Bruno M. Simões, Diane Lefley, Claudia Tulotta, Joanna Storer, Austin Gurney, Noel Clarke, Mick Brown, Sacha J. Howell, Andrew H. Sims, Gillian Farnie, Penelope D. Ottewell, Robert B. Clarke
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-15 (2019)
In breast cancer, dormant cancer cells may develop into bone metastases. Here, the authors demonstrate that microenvironmental IL1β stimulates metastatic breast cancer cell colonisation in the bone via IL1β-NFKB/CREB-Wnt pathway activation and canc
Externí odkaz:
https://doaj.org/article/c9b7748a363e46eb80d945fea7c4be66
Autor:
Richard J. Bownes, Arran K. Turnbull, Carlos Martinez-Perez, David A. Cameron, Andrew H. Sims, Olga Oikonomidou
Publikováno v:
Breast Cancer Research, Vol 21, Iss 1, Pp 1-12 (2019)
Abstract Background Neoadjuvant chemotherapy is increasingly given preoperatively to shrink breast tumours prior to surgery. This approach also provides the opportunity to study the molecular changes associated with treatment and evaluate whether on-
Externí odkaz:
https://doaj.org/article/222dc75295fc40e39ac1f9367c978a67
Autor:
Cigdem Selli, Arran K. Turnbull, Dominic A. Pearce, Ang Li, Anu Fernando, Jimi Wills, Lorna Renshaw, Jeremy S. Thomas, J. Michael Dixon, Andrew H. Sims
Publikováno v:
Breast Cancer Research, Vol 21, Iss 1, Pp 1-15 (2019)
Abstract Background The risk of recurrence for endocrine-treated breast cancer patients persists for many years or even decades following surgery and apparently successful adjuvant therapy. This period of dormancy and acquired resistance is inherentl
Externí odkaz:
https://doaj.org/article/fd063ba684234388a49de0f5201f443c
Autor:
Edward J. Jarman, Carol Ward, Arran K. Turnbull, Carlos Martinez-Perez, James Meehan, Chrysi Xintaropoulou, Andrew H. Sims, Simon P. Langdon
Publikováno v:
Breast Cancer Research, Vol 21, Iss 1, Pp 1-18 (2019)
Abstract Background Tumour hypoxia is a driver of breast cancer progression associated with worse prognosis and more aggressive disease. The cellular response to hypoxia is mediated by the hypoxia-inducible transcription factors HIF-1 and HIF-2, whos
Externí odkaz:
https://doaj.org/article/923a851c858a45a7b0788fc90b57314e
Autor:
Fuhui Chen, Sevim B. Gurler, David Novo, Cigdem Selli, Denis G. Alferez, Secil Eroglu, Kyriaki Pavlou, Jingwei Zhang, Andrew H. Sims, Neil E. Humphreys, Antony Adamson, Andrew Campbell, Owen J. Sansom, Cathy Tournier, Robert B. Clarke, Keith Brennan, Charles H. Streuli, Ahmet Ucar
Publikováno v:
Chen, F, Gurler, S B, Novo, D, Selli, C, Alferez, D G, Eroglu, S, Pavlou, K, Zhang, J, Sims, A H, Humphreys, N E, Adamson, A, Campbell, A, Sansom, O J, Tournier, C, Clarke, R B, Brennan, K, Streuli, C H & Ucar, A 2023, ' RAC1B function is essential for breast cancer stem cell maintenance and chemoresistance of breast tumor cells ', Oncogene, vol. 42, pp. 679-692 . https://doi.org/10.1038/s41388-022-02574-6
Breast cancer stem cells (BCSC) are presumed to be responsible for treatment resistance, tumor recurrence and metastasis of breast tumors. However, development of BCSC-targeting therapies has been held back by their heterogeneity and the lack of BCSC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb1327f89053608b065c8bcfc5ed3d5f
https://doi.org/10.1038/s41388-022-02574-6
https://doi.org/10.1038/s41388-022-02574-6
Publikováno v:
Breast Cancer: Basic and Clinical Research, Vol 14 (2020)
Background: Triple-negative breast cancer is an aggressive type of breast cancer with high risk of recurrence. It is still poorly understood and lacks any targeted therapy, which makes it difficult to treat. Thus, it is important to understand the un
Externí odkaz:
https://doaj.org/article/c841407e1b0c4380957860ec53d91da8
Autor:
Marta Canel, David Taggart, Andrew H Sims, David W Lonergan, Irene C Waizenegger, Alan Serrels
Publikováno v:
eLife, Vol 9 (2020)
Focal Adhesion Kinase (FAK) inhibitors are currently undergoing clinical testing in combination with anti-PD-1 immune checkpoint inhibitors. However, which patients are most likely to benefit from FAK inhibitors, and what the optimal FAK/immunotherap
Externí odkaz:
https://doaj.org/article/acfbe23a60634a70bb78633cc9dd44eb